Xenon Pharmaceuticals Inc. (XENE) PT Set at $13.00 by Jefferies Group
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) received a $13.00 target price from investment analysts at Jefferies Group in a report issued on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s price objective would indicate a potential upside of 61.49% from the stock’s previous close.
XENE has been the topic of several other research reports. Zacks Investment Research cut shares of Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 10th. Stifel Nicolaus started coverage on Xenon Pharmaceuticals in a research note on Friday, October 21st. They issued a “buy” rating and a $18.00 target price on the stock. Guggenheim started coverage on Xenon Pharmaceuticals in a research note on Monday, September 26th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Canaccord Genuity reissued a “buy” rating and issued a $16.00 target price on shares of Xenon Pharmaceuticals in a research note on Friday, August 5th. Five analysts have rated the stock with a buy rating, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $15.15.
Xenon Pharmaceuticals (NASDAQ:XENE) opened at 8.05 on Monday. Xenon Pharmaceuticals has a 52-week low of $5.65 and a 52-week high of $9.32. The company’s market capitalization is $144.04 million. The stock has a 50 day moving average price of $8.08 and a 200 day moving average price of $7.56.
Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.08. Xenon Pharmaceuticals had a negative return on equity of 34.72% and a negative net margin of 449.72%. Equities research analysts forecast that Xenon Pharmaceuticals will post ($1.57) earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of XENE. K2 Principal Fund L.P. acquired a new stake in Xenon Pharmaceuticals during the third quarter valued at about $122,000. BVF Inc. IL raised its stake in Xenon Pharmaceuticals by 75.1% in the third quarter. BVF Inc. IL now owns 3,108,905 shares of the biopharmaceutical company’s stock valued at $25,182,000 after buying an additional 1,333,333 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in Xenon Pharmaceuticals during the third quarter valued at about $1,847,000. Monashee Investment Management LLC acquired a new stake in Xenon Pharmaceuticals during the third quarter valued at about $203,000. Finally, M&T Bank Corp acquired a new stake in Xenon Pharmaceuticals during the third quarter valued at about $115,000. Institutional investors and hedge funds own 55.44% of the company’s stock.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.